Abstract
The term 'appetite suppressant' is used to denote drugs that act primarily on the neurochemical transmitters of the central nervous system to reduce food intake. In addition to drugs that release or mimic the effect of norepinephrine (noradrenaline), this could include drugs that inhibit: reuptake of norepinephrine or 5-hydroxytryptamine (also known as serotonin); bind to the γ-aminobutyric acid receptors or the cannabinoid receptors; and some peptides that reduce food intake. The sympathomimetic drugs phentermine, diethylpropion, benzphetamine, and phendimetrazine—so named because they mimic many effects of norepinephrine—are only approved in a few countries, and then only for short-term use. Sibutramine, a norepinephrine–5-hydroxytryptamine reuptake inhibitor, is approved for long-term use. Several new mechanisms for drug action are under investigation. Appetite suppressants should be viewed as useful adjuncts to diet and physical activity and might help selected patients to achieve and maintain weight loss.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bray GA and Greenway FL (1999) Current and potential drugs for treatment of obesity. Endocr Rev 20: 805–875
Bray GA and Tartaglia LA (2000) Medicinal strategies in the treatment of obesity. Nature 404: 672–677
Kroeze WK et al. (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519–526
Sykas SL et al. (1983) Anorectic drugs which stimulate thermogenesis. Life Sci 33: 1269–1275
Lupien JR and Bray GB (1986) Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue. Pharmacol Biochem Behav 25: 733–738
Hansen DL et al. (1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68: 1180–1186
Scoville BA (1975) Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgments. In Obesity in Perspective. (Ed. Bray GA) Washington DC: Department of Health, Education, and Welfare Publication NIH 75–708, 441–443
Munro JF et al. (1968) Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1: 352–354
Haddock CK et al. (2002) Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 26: 262–273
Padwal R et al. (2003) Long-term pharmacotherapy for obesity and overweight: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27: 1437–1446
Bray GA et al. (1999) Sibutramine produces dose-related weight loss. Obes Res 7: 189–198
James WPT et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM study group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119–2125
Wirth A and Krause J (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 1331–1339
McMahon FG et al. (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled multicenter trial. Arch Intern Med 160: 2185–2191
McMahon FG et al. (2002) Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16: 5–11
Hazenberg BP (2000) Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 94: 152–158
Sramek, JJ et al. (2002) Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomized trial. J Hum Hypertens 16: 13–19
Wadden RA et al. (2001) Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 161: 218–227
Ascher JA et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56: 395–401
Anderson JW et al. (2002) Bupropion SR significantly enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10: 633–641
Guy-Grand B et al. (1989) International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142–1145
Weintraub M et al. (1984) A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 144: 1143–1148
Connolly HM et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581–588
Bray GA et al. (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11: 722–733
Wilding J et al. (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28: 1399–1410
Gadde KM et al. (2003) Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289: 1820–1825
Di Marzo V et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822–825
Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285: 2486–2497
Cohen C et al. (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002 13: 451–463
Farooqi IS et al. (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341: 879–884
Considine RV et al. (1995) Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 95: 2986–2988
Friedman JM (2002) The function of leptin in nutrition, weight, and physiology. Nutr Rev 60 (Part 2): S1–S14
Morton GJ and Schwartz MW (2001) The NPY/AgRP neuron and energy homeostasis. Int J Obes Relat Metab Disord 25 (Suppl 5): S56–62
Heymsfield SB et al. (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282: 1568–1575
Lambert PD et al. (2001) Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Nat Acad Sci USA 98: 4652–4657
Ettinger MP et al. (2003) Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289: 1826–1832
Regeneron Pharmaceuticals (online 14 April 2003) Regeneron's AXOKINE® promotes weight loss in study of overweight and obese people with type 2 diabetes [http://www.regeneron.com/company/press_detail.asp?v_c_id=170] (accessed 23 December 2004)
Palmiter RD et al. (1998) Life without neuropeptide Y. Recent Prog Horm Res 53: 163–199
Ludwig DS et al. (1998) Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am J Physiol 274 (Part 1): E627–E633
Ludwig DS et al. (2001) Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 107: 379–386
Shimada M et al. (1998) Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396: 670–674
Huszar D et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131–141
Fehm HL et al. (2001) The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 86: 1144–1148
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Bray, G. Drug Insight: appetite suppressants. Nat Rev Gastroenterol Hepatol 2, 89–95 (2005). https://doi.org/10.1038/ncpgasthep0092
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0092
This article is cited by
-
The link between obesity and migraine in childhood: a systematic review
Italian Journal of Pediatrics (2017)
-
New Pharmacological Treatments for the Management of Obesity
Current Gastroenterology Reports (2014)
-
Obesity, a health burden of a global nature
Acta Pharmacologica Sinica (2012)
-
Weight Loss, HbA1c Reduction, and Tolerability of Cetilistat in a Randomized, Placebo‐controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical)
Obesity (2010)